Results 21 to 30 of about 89,305 (304)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Nature Communications, 2022
Despite effective vaccines against SARS-CoV-2, therapeutic options such as anti-virals and neutralizing antibodies are critical in treating disease, especially given the breakthrough infections of emerging VOCs. Here, Peng et al.
Lei Peng, Yingxia Hu, Madeleine C. Mankowski, Ping Ren, Rita E. Chen, Jin Wei, Min Zhao, Tongqing Li, Therese Tripler, Lupeng Ye, Ryan D. Chow, Zhenhao Fang, Chunxiang Wu, Matthew B. Dong, Matthew Cook, Guilin Wang, Paul Clark, Bryce Nelson, Daryl Klein, Richard Sutton, Michael S. Diamond, Craig B. Wilen, Yong Xiong, Sidi Chen   +23 more
doaj   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

Clinical and Developmental Immunology, 2013
Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (
Marcello Lanari, Silvia Vandini, Santo Arcuri, Silvia Galletti, Giacomo Faldella   +4 more
doaj   +1 more source

A CD3-Specific Antibody Reduces Cytokine Production and Alters Phosphoprotein Profiles in Intestinal Tissues From Patients With Inflammatory Bowel Disease [PDF]

, 2014
NOTICE: this is the author’s version of a work that was accepted for publication in Gastroenterology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms ...
Alegre, Andrew J. Stagg, André van Maurik, Anna Vossenkämper, Baumgart, Belmar, Capasso, Cardone, Chang, Christian Hundsrucker, Di Sabatino, Fedorak, Filipovich, Glocker, Herold, Hirsch, Kevin Page, Keymeulen, Keymeulen, Kotlarz, Lisa Das, Macdonald, Mehta, Monteleone, Monteleone, Monteleone, Pfaffl, Plevy, Prentice, Rovedatti, Sandborn, Schreiber, Theodore J. Sanders, Thomas T. MacDonald, Tran, van der Woude, Van Wauwe, Vossenkämper, Waldron-Lynch, Wiczling, Wu, Wu, Yu   +42 more
core   +1 more source

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. [PDF]

, 2020
On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO).
Du, Lanying, Jiang, Shibo, Ojcius, David M, Pan, Chungen, Yu, Fei   +4 more
core   +1 more source

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

Antibodies, 2019
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole ...
Erik Doevendans, Huub Schellekens
doaj   +1 more source

Functional epitopes and neutralizing antibodies of vaccinia virus

Frontiers in Microbiology, 2023
Smallpox is an infectious disease caused by the variola virus, and it has a high mortality rate. Historically it has broken out in many countries and it was a great threat to human health.
Fenghao Peng, Naijing Hu, Yingjun Liu, Cong Xing, Longlong Luo, Xinying Li, Jing Wang, Guojiang Chen, He Xiao, Chenghua Liu, Beifen Shen, Jiannan Feng, Chunxia Qiao   +12 more
doaj   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45

Nature Communications, 2018
Malaria protein Pfs48/45 is a promising transmission-blocking antigen targeted by antibodies. Here, the authors determine the structure of its transmission-blocking epitope I, and generate a humanized monoclonal antibody that binds Pfs48/45 with high ...
Prasun Kundu, Anthony Semesi, Matthijs M. Jore, Merribeth J. Morin, Virginia L. Price, Alice Liang, Jingxing Li, Kazutoyo Miura, Robert W. Sauerwein, C. Richter King, Jean-Philippe Julien   +10 more
doaj   +1 more source